

# Supplementary figures

Following supplementary figures depict the molecular structure of iBodies used in this thesis.

**Supplementary figure 1 (p. 2): Structure of iBody 1**


**Supplementary figure 2 (p. 3): Structure of iBody 2**

**Supplementary figure 3 (p. 4): Structure of iBody 3**


**Supplementary figure 4 (p. 5): Structure of iBody 4**

**Supplementary figure 5 (p. 6): Structure of iBody 5**


**Supplementary figure 6 (p. 7): Structure of iBody 6**




**Supplementary figure 1: Structure of iBody 1.** iBody 1, targeting GCPII, contains Compound 1 (GCPII inhibitor), ATTO 488, and biotin.




**Supplementary figure 2: Structure of iBody 2.** iBody 2, targeting HIV-1 protease, contains Compound 2 (a derivative of an HIV-1 protease inhibitor ritonavir), and biotin.




**Supplementary figure 3: Structure of iBody 3.** iBody 3, targeting aspartic proteases, contains Compound 3 (a derivative of an aspartic proteases inhibitor pepstatin A), and biotin.



**Supplementary figure 4: Structure of iBody 4.** iBody 4, targeting His-tagged proteins, contains Compound 4 (a derivative of a nitrilotriacetic acid), biotin, and ATTO 488.



**Supplementary figure 5: Structure of iBody 5.** iBody 5, serving as a negative control for iBodies 1 and 4, contains biotin and ATTO 488.



**Supplementary figure 6: Structure of iBody 6.** iBody 6, serving as a negative control for iBodies 2 a 3, contains only biotin.